Arcturus raises $50 million from Meiji for 7.9% stake after deal
Key Facts
Arcturus Therapeutics announced on November 16 an agreement under which Meiji Seika Pharma will purchase $50 million of unregistered securities. The agreement set the purchase price at $20.27 per share, representing 7.9% of Arcturus’ shares outstanding after the deal closes. The company said the investment coincides with a separate exclusive license agreement to apply ARCT-154 in an undisclosed therapeutic area. The two companies also signed a memorandum of understanding outlining key terms for a potential collaboration and license agreement for a Japanese pandemic preparedness and response program using Arcturus’ platform. The arrangements therefore combine a defined investment, an existing license agreement and a collaboration initiative that remains potential.
Chief Executive Joseph Payne said the investment proceeds will be used to accelerate development of ARCT-2601 for OTC deficiency, alongside the cystic fibrosis program. The candidate is the company’s first messenger RNA therapeutic to use its LUNAR 2.0 delivery platform. Arcturus plans to begin Phase 2 dosing in the first quarter of 2027, targeting preliminary data in the second half of the year. Payne said the proceeds would support accelerated development of the treatment, linking the new funding to a specific clinical program. The stated use places the deal proceeds within the company’s plans to develop its therapies and clinically validate its platform.
The deal comes as Arcturus’ financial figures showed cash and cash equivalents falling to $184.8 million on September 30, 2026, from $230.9 million on December 31, 2025. The decline totaled $46.1 million between the two dates. The company attributed the decrease mainly to clinical development spending, including its cystic fibrosis and OTC deficiency programs. A $12 million payment from CSL Seqirus offset part of the decline. In the third quarter of 2026, the company reported revenue of $18.3 million, compared with $17.2 million in the same period of 2025.
Revenue for the first nine months of 2026, however, was $23.3 million, compared with $74.8 million in the corresponding period of 2025. Meiji and CSL Seqirus continue to be responsible for marketing it in Japan during the season expected to end on or around June 30, 2027. Arcturus shares closed at $8.36 on November 13, 2026, before the deal was announced. Meiji shares, listed under the ticker 2269.T, also closed at 4,428 yen on the same date.